Petra Bělohlávková

Author

Petra Bělohlávková

University Hospital Hradec Králové ORCID

Also Known As

Belohlavkova, Petra, P Belohlavkova, P Bělohlávková, P. BELOHLAVKOVA, P. Belohlavkova, P. Bělohlávková, Petra Belohlavkova, Petra Bělohlávková

Publications

342

Citations

H-Index

Concepts

All Affiliations

University Hospital Hradec Králové Charles University Institute of Haematology and Blood Transfusion University Hospital Brno University Hospital Olomouc

About

Petra Bělohlávková is an author at University Hospital Hradec Králové specializing in hematology, medicine, and thrombosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	175
2	Hematology	3	3	175
3	Health Sciences	1	1	30
4	Orthopaedics	1	1	27
5	Pathology	1	1	30

Petra Bělohlávková

Publications

229

Citations

H-Index

Page 1

	Year	Citations
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial Uwe Platzbecker, Valeria Santini, Pierre Fenaux, The Lancet Hematological MalignancyThrombosisErythropoiesis-stimulating AgentsBone Marrow FailureMalignant Blood Disorder	2023	118
Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia J Voglová, Edgar Faber, Daniela Žáčková, Neoplasma Hematological MalignancyChronic Myeloid LeukemiaMedicineMixed-phenotype Acute LeukemiaMalignant Blood Disorder	2011	30
A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes Jaroslav Čermák, Anna Jonášová, Jana Vondráková, Leukemia Research Bone Marrow FailureIron MetabolismAplastic AnemiaIron OverloadHematology	2013	27
Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment Monika Jaruskova, Nikola Čuřík, Rajna Hercog, Journal of Experimental & Clinical Cancer Research	2017	25
The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients Petra Bělohlávková, Filip Vrbacký, J Voglová, Archives of Medical Science	2018	17
Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy – Results of Enigma 2 Study Zdeněk Ráčil, Petra Bělohlávková, Petr Cetkovský, Blood	2014	12

Page 1